In Segment C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will acquire treatment right up until sickness progression or maybe the contributors are unable to tolerate the study drugs. For all stream cytometry experiments, ten,000 cells for every replicate were https://carlosw100jue2.governor-wiki.com/user